Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07445022Phase 4Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tunlametinib in melanoma, sponsored by Fudan University. Started Jan 2026; status: recruiting.
02
Drugs
tunlametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07445022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445022.